MEPSEVII

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MEPSEVII (MEPSEVII).

How it works

MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).

What the body does with it

Metabolism	Vestronidase alfa is a protein; expected to be degraded into small peptides and amino acids via general protein catabolism pathways.
Excretion	Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Half-life	Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Protein binding	Negligible (<1%); not bound to plasma proteins.
Volume of Distribution	Volume of distribution (Vd): approximately 0.3 L/kg (range 0.2–0.5 L/kg), consistent with limited extravascular distribution.
Bioavailability	Bioavailability: 100% intravenous; not administered via other routes.
Onset of Action	Intravenous: reduction in urinary glycosaminoglycan (GAG) levels observed within 4 weeks of initiating weekly infusion.
Duration of Action	Sustained reduction in urinary GAG levels over 48 weeks of treatment; clinical effects on hepatosplenomegaly and other manifestations persist with continued weekly dosing.

Classification & Brands

Dosing & administration

1 mg/kg administered intravenously once weekly over 4 hours.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for renal impairment; safety and efficacy not established in severe renal impairment.
Liver impairment	No dose adjustment required for hepatic impairment.
Pediatric use	1 mg/kg administered intravenously once weekly over 4 hours; safety and efficacy established in pediatric patients.
Geriatric use	No specific dose adjustment recommended; use with caution due to limited data in elderly patients.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MEPSEVII (MEPSEVII).

Breastfeeding	No data on presence in human milk; MEPSEVII is a recombinant enzyme likely degraded in the GI tract; consider developmental and health benefits of breastfeeding alongside maternal need for drug.
Teratogenic Risk	Insufficient human data; animal studies show no teratogenic effects at doses up to 10 times the human dose. Fetal risk cannot be excluded. Use only if maternal benefit outweighs potential fetal risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

There is no FDA black box warning for MEPSEVII.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Life-threatening hypersensitivity reaction to vestronidase alfa or any excipient"]

Clinical Precautions

Precautions

["Risk of severe hypersensitivity reactions including anaphylaxis","Infusion-associated reactions (fever, chills, rash, urticaria)","Acute respiratory distress in patients with underlying respiratory compromise"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MEPSEVII

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MEPSEVII (MEPSEVII).

How it works

What the body does with it

Metabolism	Vestronidase alfa is a protein; expected to be degraded into small peptides and amino acids via general protein catabolism pathways.
Excretion	Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Half-life	Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Protein binding	Negligible (<1%); not bound to plasma proteins.
Volume of Distribution	Volume of distribution (Vd): approximately 0.3 L/kg (range 0.2–0.5 L/kg), consistent with limited extravascular distribution.
Bioavailability	Bioavailability: 100% intravenous; not administered via other routes.
Onset of Action	Intravenous: reduction in urinary glycosaminoglycan (GAG) levels observed within 4 weeks of initiating weekly infusion.
Duration of Action	Sustained reduction in urinary GAG levels over 48 weeks of treatment; clinical effects on hepatosplenomegaly and other manifestations persist with continued weekly dosing.

Classification & Brands

Dosing & administration

1 mg/kg administered intravenously once weekly over 4 hours.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for renal impairment; safety and efficacy not established in severe renal impairment.
Liver impairment	No dose adjustment required for hepatic impairment.
Pediatric use	1 mg/kg administered intravenously once weekly over 4 hours; safety and efficacy established in pediatric patients.
Geriatric use	No specific dose adjustment recommended; use with caution due to limited data in elderly patients.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MEPSEVII (MEPSEVII).

Breastfeeding	No data on presence in human milk; MEPSEVII is a recombinant enzyme likely degraded in the GI tract; consider developmental and health benefits of breastfeeding alongside maternal need for drug.
Teratogenic Risk	Insufficient human data; animal studies show no teratogenic effects at doses up to 10 times the human dose. Fetal risk cannot be excluded. Use only if maternal benefit outweighs potential fetal risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

There is no FDA black box warning for MEPSEVII.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Life-threatening hypersensitivity reaction to vestronidase alfa or any excipient"]